AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Pulmonary Embolism in Patients With Acute Heart Failure (PEHF Study)

RecruitingNAAges 18 Years - anyAllUniversity Hospital, Angers
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study focuses on two serious and common medical conditions: heart failure and pulmonary embolism (a blood clot in the lungs). Heart failure happens when the heart cannot pump blood effectively, and it is one of the main reasons older adults are admitted to the hospital. Pulmonary embolism can be life-threatening and may worsen heart failure or even trigger it. Doctors believe that pulmonary embolism may often go undetected in patients who come to the hospital with symptoms of acute heart failure, such as sudden shortness of breath. This is because both conditions can cause similar symptoms, making it difficult to tell them apart. As a result, doctors may sometimes assume the symptoms are only due to heart failure and not investigate further for a possible blood clot. However, missing a pulmonary embolism can have serious consequences. Studies suggest that some patients with heart

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adult patient (โ‰ฅ18 years) * Admission to the emergency department or cardiology unit of a participating center * Recent onset or worsening dyspnea and/or orthopnea * Diagnosis of acute heart failure defined by recent dyspnea associated with at least one of the following: * Bilateral pulmonary crackles on auscultation and/or peripheral edema * Signs of pulmonary congestion on chest X-ray or lung/cardiac ultrasound * Elevated natriuretic peptide levels (BNP or NT-proBNP) * Documented history of heart failure (known chronic heart failure or prior hospitalization for acute heart failure) * Patient affiliated with or beneficiary of a social security system * Patient able and willing to provide free, informed, and written consent Exclusion Criteria: * Shock state suggesting cardiogenic shock and/or severe pulmonary embolism * Severe respiratory distress at inclusion preventing appropriate positioning or performance of imaging examinations * Evidence of acute coronary syndrome on electrocardiogram at admission * Severe renal impairment (creatinine clearance \<30 mL/min) * Known hypersensitivity or allergy to iodinated contrast agents * Ongoing therapeutic anticoagulation for more than 48 hours prior to admission * Hospitalization for more than 48 hours prior to inclusion * Inability to ensure 90-day follow-up (e.g., end-of-life situation, no fixed address, patient not reachable) * Inadequate understanding of the French language preventing proper study information and consent * Pregnant, breastfeeding, or postpartum women * Individuals under legal protection or other vulnerable populations, including minors and protected adults, in accordance with applicable public health regulations (Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code)
๐Ÿ’Š

What it tests

  • Systematic screening for pulmonary embolism in all patients using a guideline-recommended diagnostic algorithm
๐Ÿ“

Where

10 sites
Agen Hospital, Emergency department
Agen, France
Angers University Hospital, Emergency Department
Angers, France
Brest University Hospital (site Cavale Blanche), Cardiology Department
Brest, France
Tours University Hospital (site Trousseau), Adult Emergency Department
Chambray-lรจs-Tours, France
Cholet Hospital, Emergency Department
Cholet, France
Clermont-Ferrand University Hospital, Emergency Department
Clermont-Ferrand, France
Grenoble Alpes University Hospital, Adult Emergency Department
La Tronche, France
Lyon University Hospital (site Edouard Herriot), Emergency Department
Lyon, France

โ€ฆand 2 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy